Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 9/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665832 | 1.00 | TRPA1 (0.46) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24513101 | 0.94 | AR (0.51) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL29665924 | 0.94 | AR (0.51) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL29665891 | 0.91 | AR (0.48) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24632285 | 0.91 | AR (0.48) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24512989 | 0.90 | PLA2G7 (0.45) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL29666010 | 0.90 | PLA2G7 (0.45) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24512799 | 0.89 | AR (0.48) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24513083 | 0.89 | AR (0.46) | TRPA1TAS1R3TAS1R1TAS1R2AR | |
| SCHEMBL24512800 | 0.89 | AR (0.48) | TRPA1TAS1R3TAS1R1TAS1R2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11952346-B2 | Modulators of mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4259604-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20220340530-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220340530-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022125636-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125636-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952346-B2 | Modulators of mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | TRPA1 997/4885TAS1R3 468/4885TAS1R1 575/4885 |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | TRPA1 997/4885TAS1R3 468/4885TAS1R1 575/4885 |
| US-20220340530-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | TRPA1 997/4885TAS1R3 468/4885TAS1R1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.